Ascentage Pharma Group International
Ascentage Pharma Group International Fundamental Analysis
Ascentage Pharma Group International (ASPHF) shows moderate financial fundamentals with a PE ratio of -30.64, profit margin of -3.44%, and ROE of -1.40%. The company generates $0.2B in annual revenue with moderate year-over-year growth of 3.42%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -387.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ASPHF's fundamental strength across five key dimensions:
Efficiency Score
WeakASPHF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentASPHF trades at attractive valuation levels.
Growth Score
ModerateASPHF shows steady but slowing expansion.
Financial Health Score
ModerateASPHF shows balanced financial health with some risks.
Profitability Score
WeakASPHF struggles to sustain strong margins.
Key Financial Metrics
Is ASPHF Expensive or Cheap?
P/E Ratio
ASPHF trades at -30.64 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ASPHF's PEG of 0.03 indicates potential undervaluation.
Price to Book
The market values Ascentage Pharma Group International at 29.87 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -42.76 times EBITDA. This is generally considered low.
How Well Does ASPHF Make Money?
Net Profit Margin
For every $100 in sales, Ascentage Pharma Group International keeps $-3.44 as profit after all expenses.
Operating Margin
Core operations generate -3.35 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.40 in profit for every $100 of shareholder equity.
ROA
Ascentage Pharma Group International generates $-21.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ascentage Pharma Group International generates strong operating cash flow of $196.38M, reflecting robust business health.
Free Cash Flow
Ascentage Pharma Group International generates weak or negative free cash flow of $-236.17M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.64 in free cash annually.
FCF Yield
ASPHF converts -1.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-30.64
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
29.87
vs 25 benchmark
P/S Ratio
Price to sales ratio
114.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.58
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.40
vs 25 benchmark
ROA
Return on assets percentage
-0.21
vs 25 benchmark
ROCE
Return on capital employed
-0.35
vs 25 benchmark
How ASPHF Stacks Against Its Sector Peers
| Metric | ASPHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -30.64 | 29.45 | Better (Cheaper) |
| ROE | -139.59% | 779.00% | Weak |
| Net Margin | -343.75% | -24936.00% (disorted) | Weak |
| Debt/Equity | 2.58 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.54 | 4.65 | Neutral |
| ROA | -21.31% | -19344.00% (disorted) | Weak |
ASPHF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ascentage Pharma Group International's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
2511.16%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
89.42%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
90.65%
Industry Style: Defensive, Growth, Innovation
High Growth